KAOHSIUNG MEDICAL UNIVERSITY

The Fourth Asia-Pacific Forum on Precision Cancer Treatment highlighted advancements in breast and lung cancer care, focusing on liquid biopsy, personalized therapies, and in-depth genetic profiling. Experts discussed how these innovations enhance early detection, monitor tumor heterogeneity, and tailor treatments to improve outcomes. The forum emphasized the importance of a complete ecosystem in precision medicine, spanning detection to treatment, and the role of international collaboration in advancing cancer care.

Dr. George Tsai founded AMS BioteQ in 2018, focusing on drug development and innovative medical materials research, leveraging Taiwan’s unique natural resources to combat infectious diseases and expand into the global anti-infection market. The company successfully isolated compounds YUAN-01 and YUAN-03 from Antrodia camphorata, showing excellent antibacterial properties, and later identified potential antiviral effects against COVID-19. AMS BioteQ also targets Dengue, Zika, and Avian Influenza viruses, with compounds like AMS-2140 showing strong antiviral effects in animal experiments. The company employs early licensing strategies to secure funding and collaborates with international partners for clinical trials. Additionally, AMS BioteQ develops innovative medical devices like the SIPSIP Foam Dressing for wound care, targeting the Japanese market, and plans to launch multiple dressing products by 2026.

HCV infection may increase PAD risk in ESRD patients on hemodialysis, linked to elevated baPWV levels. Higher viral load and genotype 1 significantly associated with increased PAD risk.